Valuation : MaaT Pharma

Market Cap 51.54M 59.82M 48.8M 44.23M 82.98M 5.71B 83.4M 580M 223M 2.91B 225M 220M 9.19B P/E 2026 *
-1.43x
P/E 2027 * -2.46x
Enterprise Value 62.84M 72.94M 59.5M 53.93M 101M 6.97B 102M 707M 272M 3.54B 274M 268M 11.2B EV / Sales 2026 *
6.44x
EV / Sales 2027 * 2.98x
Free-Float
36.85%
Yield 2026 *
-
Yield 2027 * -
1 day-1.97%
1 week-6.97%
Current month-7.60%
1 month-4.37%
3 months-3.36%
6 months-61.69%
Current year-43.14%
1 week 2.65
Extreme 2.65
2.96
1 month 2.65
Extreme 2.65
3.4
Current year 2.32
Extreme 2.32
8.62
1 year 2.32
Extreme 2.32
8.62
3 years 2.32
Extreme 2.32
9.96
5 years 2.32
Extreme 2.32
14.4
10 years 2.32
Extreme 2.32
14.4
Manager TitleAgeSince
Chief Executive Officer - 01/01/2014
Director of Finance/CFO 59 01/11/2024
Chief Tech/Sci/R&D Officer - 24/06/2024
Director TitleAgeSince
Director/Board Member - 01/01/2014
Director/Board Member 57 01/01/2014
Chairman - 01/01/2016
Date Insider Type Main position Quantity % Market Cap. Importance
28/05/26 Buy

Founder

2,000 0.0106%
29/01/26
Seventure Partners SA
SellCompany 25,423 0.1356%
28/01/26
Seventure Partners SA
SellCompany 57,964 0.3091%
Change 5-day change 1-year change 3-year change Capi.($)
-1.97%-6.97%-36.69%-57.00% 59.82M
-2.11%-1.68%+44.52%+95.15% 66.93B
-0.23%-4.45%+30.39%+73.64% 61.97B
+1.67%+2.47%-11.23%+388.34% 28.27B
-1.05%-4.43%+30.56%+10.07% 24.59B
+0.34%-6.78%-7.27%-17.99% 24.3B
+0.43%-3.37%+14.85%-19.29% 19.41B
-3.03%-2.29%+185.12%+334.07% 16.77B
-1.94%-4.94%-5.29%+495.65% 14.18B
-2.28%-4.90%+43.64%+155.21% 13.91B
Average -1.02%-3.81%+28.86%+145.78% 27.04B
Weighted average by Cap. -0.84%-3.06%+33.45%+133.63%

Financials

2026 *2027 *
Net sales 9.75M 11.32M 9.23M 8.37M 15.7M 1.08B 15.78M 110M 42.17M 550M 42.5M 41.57M 1.74B 28.88M 33.52M 27.34M 24.78M 46.5M 3.2B 46.73M 325M 125M 1.63B 126M 123M 5.15B
Net income -31.69M -36.78M -30.01M -27.2M -51.03M -3.51B -51.29M -356M -137M -1.79B -138M -135M -5.65B -15.31M -17.77M -14.5M -13.14M -24.65M -1.7B -24.78M -172M -66.21M -864M -66.74M -65.27M -2.73B
Net Debt 11.3M 13.12M 10.7M 9.7M 18.2M 1.25B 18.29M 127M 48.89M 638M 49.27M 48.19M 2.02B 34.5M 40.04M 32.67M 29.61M 55.55M 3.83B 55.83M 388M 149M 1.95B 150M 147M 6.15B
Logo MaaT Pharma
MaaT Pharma is a late-stage biotechnology company and a leader in the development of intestinal microbiota-based drugs designed to modulate the immune system of cancer patients and improve their survival. A pioneer in its field, MaaT Pharma is developing the first immunomodulatory drug candidate based on intestinal microbiota in oncology, currently in phase 3 clinical evaluation. Thanks to its proprietary pooling (combining donations of healthy microbiota) and microbial co-culture technologies, MaaT Pharma is developing standardised drugs with high bacterial diversity, aimed at improving the survival of cancer patients.
Employees
56
Date Price Change Volume
11/09/26 €2.735 -1.97% 33,087
10/09/26 €2.790 +5.08% 38,283
09/09/26 €2.655 -5.18% 34,428
08/09/26 €2.800 -2.78% 35,012
07/09/26 €2.880 -2.04% 28,531
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.735EUR
Average target price
6.500EUR
Spread / Average Target
+137.66%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MAAT Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!